Phaseline

Targets › PHD1

PHD1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Hematology; next expected readout Dec 2027.

Open in Phaseline: the race on PHD1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ascentage Pharma GroupAPG-5918
HIF-PHD inhibitor
PHD1, PHD2, PHD3Phase 1AnemiaDec 2027

Conditions

Anemia (1)

Modalities

small molecule (1)

Companies

Ascentage Pharma Group (1)

Related targets

PHD2 (1) PHD3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.